Manufacturer profile
UPSA SAS, France
Every published regulatory action recorded against this manufacturer, across all African authorities Drug Eye Africa monitors. Built strictly from published regulatory decisions and nothing else.
What these numbers are. They are counts of published regulatory actions recorded on this register. They are not a finding about the company, not an allegation, and not a measure of product quality. A manufacturer appearing here has had actions published against named products by named authorities; the actions speak for themselves and each one links to its primary notice.
3
Recorded actions
1
Countries
1
Authorities
0
Class I actions recorded
| Reference | Date | Ctry | Product | Batches | Action | Class | Source |
|---|---|---|---|---|---|---|---|
| DEA-RW-2025-27638088 | 23 Apr 2025 | RW | Aspirine vitammin C 330MG/200 mg BN: B6224, Exp. 08/2026 UPSA SAS, France | B6224 | Recall | Class II | Tier 1 · Regulator-published |
| DEA-RW-2024-93587290 | 10 Oct 2024 | RW | Efferalgan Vitamine C UPSA SAS, France | A6091 | Recall | Class II | Tier 1 · Regulator-published |
| DEA-RW-2024-72064395 | 30 Jun 2024 | RW | Efferalgan vitamine c 500mg/200mg UPSA SAS, France | A4042 | Recall | Class II | Tier 1 · Regulator-published |
Counts are of published regulatory actions recorded on this register. They are not a finding about the company, and this page says so.
Names as published
The issuing authorities published this name as: UPSA SAS, France.
Company response
No response filed. Any named company may register and publish a reply beside these records, and the invitation is logged whether or not it is answered.
How this page is built
- Published regulator decisions only — no press reports, no allegations
- Name matching is conservative: only corporate-form suffixes are stripped, and a name that would reduce to a single token is kept whole
- Every action links to its primary notice